Suppr超能文献

外照射放疗中断对前列腺癌患者治疗结果的影响。

Effects of interruptions of external beam radiation therapy on outcomes in patients with prostate cancer.

作者信息

Dong Yanqun, Zaorsky Nicholas G, Li Tianyu, Churilla Thomas M, Viterbo Rosalia, Sobczak Mark L, Smaldone Marc C, Chen David Yt, Uzzo Robert G, Hallman Mark A, Horwitz Eric M

机构信息

Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.

Department of Radiation Oncology, Penn State Cancer Institute, Hershey, Pennsylvania, USA.

出版信息

J Med Imaging Radiat Oncol. 2018 Feb;62(1):116-121. doi: 10.1111/1754-9485.12675. Epub 2017 Oct 13.

Abstract

INTRODUCTION

To evaluate if interruptions of external beam radiation therapy impact outcomes in men with localized prostate cancer (PCa).

METHODS

We included men with localized PCa treated with three-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) of escalated dose (≥74 Gy in 1.8 or 2 Gy fractions) between 1992 and 2013 at an NCI-designated cancer centre. Men receiving androgen deprivation therapy were excluded. The non-treatment day ratio (NTDR) was defined as the number of non-treatment days divided by the total elapsed days of therapy. NTDR was analysed for each National Comprehensive Cancer Network (NCCN) risk group.

RESULTS

There were 1728 men included (839 low-risk, 776 intermediate-risk and 113 high-risk), with a median follow up of 53.5 months (range 12-185.8). The median NTDR was 31% (range 23-71%), translating to approximately 2 breaks (each break represents a missed treatment that will be made up) for 8 weeks of RT with 5 treatments per week. The 75 percentile of NTDR was 33%, translating to approximately 4 breaks, which was used as the cutoff for analysis. There were no significant differences in freedom from biochemical failure, freedom from distant metastasis, cancer specific survival, or overall survival for men with NTDR ≥33% compared to NTDR<33% for each risk group. Multivariable analyses including NTDR, age, race, Gleason score, T stage, and PSA were performed using the proportional hazards regression procedure. NTDR≥33% was not significantly associated with increased hazard ratio for outcomes in each risk group compared to NTDR<33%.

CONCLUSION

Unintentional treatment breaks during dose escalated external beam radiation therapy for PCa did not cause a significant difference in outcomes, although duration of follow up limits the strength of this conclusion.

摘要

引言

评估外照射放疗中断是否会影响局限性前列腺癌(PCa)男性患者的治疗结果。

方法

我们纳入了1992年至2013年期间在一家美国国立癌症研究所指定的癌症中心接受三维适形放疗(3D-CRT)或剂量递增(≥74 Gy,每次分割剂量为1.8或2 Gy)的调强放疗(IMRT)的局限性PCa男性患者。接受雄激素剥夺治疗的男性被排除在外。非治疗日比率(NTDR)定义为非治疗天数除以治疗总天数。对每个美国国立综合癌症网络(NCCN)风险组的NTDR进行分析。

结果

共纳入1728名男性(839名低风险、776名中风险和113名高风险),中位随访时间为53.5个月(范围12 - 185.8个月)。NTDR的中位数为31%(范围23% - 71%),这意味着每周进行5次放疗、共8周的疗程中大约有2次中断(每次中断代表一次错过但后续会补上的治疗)。NTDR的第75百分位数为33%,即大约4次中断,以此作为分析的临界值。对于每个风险组,NTDR≥33%的男性与NTDR<33%的男性相比,在无生化复发、无远处转移、癌症特异性生存或总生存方面均无显著差异。使用比例风险回归程序对包括NTDR、年龄、种族、Gleason评分、T分期和前列腺特异性抗原(PSA)在内的多变量进行分析。与NTDR<33%相比,NTDR≥33%在每个风险组中与结局的风险比增加均无显著相关性。

结论

尽管随访时间限制了该结论的力度,但在局限性PCa的剂量递增外照射放疗期间,无意的治疗中断并未导致治疗结果出现显著差异。

相似文献

1
Effects of interruptions of external beam radiation therapy on outcomes in patients with prostate cancer.
J Med Imaging Radiat Oncol. 2018 Feb;62(1):116-121. doi: 10.1111/1754-9485.12675. Epub 2017 Oct 13.
3
Does treatment duration affect outcome after radiotherapy for prostate cancer?
Int J Radiat Oncol Biol Phys. 2008 Dec 1;72(5):1402-7. doi: 10.1016/j.ijrobp.2008.03.011. Epub 2008 May 9.
6
Interval to biochemical failure predicts clinical outcomes in patients with high-risk prostate cancer treated by combined-modality radiation therapy.
Int J Radiat Oncol Biol Phys. 2013 Jul 15;86(4):721-8. doi: 10.1016/j.ijrobp.2013.03.028. Epub 2013 May 9.
10
Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era?
Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):693-9. doi: 10.1016/j.ijrobp.2012.06.030. Epub 2012 Jul 24.

引用本文的文献

2
Treatment Interruptions During Stereotactic Body Radiotherapy for Prostate Cancer.
Front Oncol. 2022 Jan 19;11:796496. doi: 10.3389/fonc.2021.796496. eCollection 2021.
4
Optimal timing of radiotherapy in high risk prostate cancer: Do missed days matter?
Clin Transl Radiat Oncol. 2020 Nov 25;26:47-54. doi: 10.1016/j.ctro.2020.11.006. eCollection 2021 Jan.
6
Covert COVID-19: Cone Beam Computed Tomography Lung Changes in an Asymptomatic Patient Receiving Radiation Therapy.
Adv Radiat Oncol. 2020 May 19;5(4):715-721. doi: 10.1016/j.adro.2020.04.029. eCollection 2020 Jul-Aug.
7
[Practical update of total dose compensation in case of temporary interruption of external radiotherapy in the COVID-19 pandemic context].
Cancer Radiother. 2020 Jun;24(3):182-187. doi: 10.1016/j.canrad.2020.04.001. Epub 2020 Apr 10.
8
Twice- vs. thrice-weekly moderate hypofractionated radiotherapy for prostate cancer: does overall treatment time matter?
J Cancer Res Clin Oncol. 2019 Jun;145(6):1581-1588. doi: 10.1007/s00432-019-02893-4. Epub 2019 Mar 18.

本文引用的文献

2
Causes of death among cancer patients.
Ann Oncol. 2017 Feb 1;28(2):400-407. doi: 10.1093/annonc/mdw604.
3
Necroptosis in tumorigenesis, activation of anti-tumor immunity, and cancer therapy.
Oncotarget. 2016 Aug 30;7(35):57391-57413. doi: 10.18632/oncotarget.10548.
4
Comparison of outcomes and toxicities among radiation therapy treatment options for prostate cancer.
Cancer Treat Rev. 2016 Jul;48:50-60. doi: 10.1016/j.ctrv.2016.06.006. Epub 2016 Jun 17.
5
Hypofractionated radiotherapy for organ-confined prostate cancer: is less more?
Nat Rev Urol. 2016 Jul;13(7):400-8. doi: 10.1038/nrurol.2016.106. Epub 2016 Jun 14.
6
Impact of Radiation Therapy Dose Escalation on Prostate Cancer Outcomes and Toxicities.
Am J Clin Oncol. 2018 Apr;41(4):409-415. doi: 10.1097/COC.0000000000000285.
7
Mesenchymal stem cells generate pericytes to promote tumor recurrence via vasculogenesis after stereotactic body radiation therapy.
Cancer Lett. 2016 Jun 1;375(2):349-359. doi: 10.1016/j.canlet.2016.02.033. Epub 2016 Mar 17.
8
Survival Impact of Increasing Time to Treatment Initiation for Patients With Head and Neck Cancer in the United States.
J Clin Oncol. 2016 Jan 10;34(2):169-78. doi: 10.1200/JCO.2015.61.5906. Epub 2015 Nov 30.
9
Pericytes: a double-edged sword in cancer therapy.
Future Oncol. 2015;11(1):169-79. doi: 10.2217/fon.14.123.
10
Cancer statistics, 2014.
CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29. doi: 10.3322/caac.21208. Epub 2014 Jan 7.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验